PRISM BioLab Co. LTD
TTSE:206ATotal Valuation
JPYAs of March 31, 2026, PRISM BioLab Co. LTD carries a market capitalization of 6.62B, placing it among publicly traded companies globally. Its enterprise value stands at 4.16B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 6.62B |
| Enterprise Value | 4.16B |
Important Dates
PRISM BioLab Co. LTD's next confirmed earnings release is scheduled for November 13, 2026.
| Earnings Date | 11/13/2026 |
Share Statistics
As of March 31, 2026, PRISM BioLab Co. LTD has 36.96M shares outstanding.
| Shares Outstanding | 36.96M |
Valuation Ratios
These figures are as of March 31, 2026.
| PB Ratio | 3.11 |
| P/TBV Ratio | 3.11 |
Financial Position
As of March 31, 2026, PRISM BioLab Co. LTD maintains a current ratio of 5.65, meaning it holds 5.7x the short-term assets needed to cover near-term liabilities.
| Current Ratio | 5.65 |
| Quick Ratio | 5.46 |
Financial Efficiency
These figures cover the twelve months ended March 31, 2026.
| Employee Count | 35.00 |
Stock Price Statistics
JPYAs of the close on October 23, 2026, PRISM BioLab Co. LTD's stock has declined approximately 21.43% over the past 52 weeks. The 50-day moving average sits at 160.02, while the 200-day moving average is 168.25.
| 52-Week Price Change | -21.43% |
| 50-Day Moving Average | 160.02 |
| 200-Day Moving Average | 168.25 |
Balance Sheet
JPYThese figures are as of March 31, 2026. Total book value stands at 2.13B, with working capital of 2.09B providing operational flexibility.
| Cash & Cash Equivalents | 2.45B |
| Net Debt | -2.45B |
| Equity (Book Value) | 2.13B |
| Book Value Per Share | 57.62 |
| Working Capital | 2.09B |